Jakavi 15mg (Ruxolitinib Tablet) 15mg

Jakavi 15mg (Ruxolitinib) is an oral tablet used for certain blood disorders. This JAK inhibitor helps regulate immune responses. Store at room temperature and keep out of reach of children. Always follow healthcare provider instructions.

Strength

15mg

Pack Size

60s

Storage

Ambient

Manufacturer / TM Owner

Novartis Pharma Stein AG

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Jakavi 15mg (Ruxolitinib) is used to treat myelofibrosis and polycythemia vera, conditions affecting bone marrow function. It may also be prescribed for graft-versus-host disease in some cases. This medication helps reduce symptoms like enlarged spleen and fatigue. Patients often ask what is Jakavi 15mg used for in managing chronic conditions.

Side Effects

Many patients report improved energy levels and reduced discomfort after starting Jakavi 15mg. Some experience changes in blood cell counts as the medication takes effect. Digestive comfort and reduced inflammation are common observations. Individual responses may vary based on condition and treatment duration.

Precautions & Warnings

Keep Jakavi 15mg in its original packaging at room temperature. Avoid exposure to moisture or direct sunlight. Do not share this medication with others, even if they have similar symptoms. Regular blood tests may be required to monitor treatment progress and safety.

Avoid Interactions

Jakavi 15mg may interact with certain antifungals, antibiotics, or herbal supplements. Grapefruit products can affect how the body processes this medication. Always inform your healthcare provider about all medications and supplements you take. Some interactions may require dose adjustments or monitoring.

Frequently Asked Questions

Jakavi 15mg is used to treat myelofibrosis and polycythemia vera, conditions that affect bone marrow function.

Store Jakavi 15mg at room temperature in its original packaging, away from moisture and direct sunlight.

Consult your healthcare provider before combining Jakavi with other medications or supplements to avoid potential interactions.

Common effects may include changes in blood cell counts, digestive discomfort, or fatigue. Individual responses vary.

This medication should only be used during pregnancy if clearly needed and prescribed by a healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.